In a study published today, Waisman Center investigators Su-Chun Zhang, Albee Messing and colleagues point to new understandings of the broad range of effects that result from the GFAP mutation impacting astrocytes — important supporting …
Stem Cells
Scientists seek to improve quality control for genome editing therapies in the eye
Waisman Center investigator David Gamm, MD, PhD, and affiliate Krishanu Saha, PhD, are part of a team of scientists at the University of Wisconsin- Madison who were recently granted a major award from the National …
Twenty years of stem cells
In 1998, UW–Madison developmental biologist James Thomson introduced the world to the first laboratory-derived human embryonic stem cells. Twenty years later, UW–Madison remains at the forefront of stem cell research. The Waisman Center at UW-Madison …
Blockages in nerve-cell protein ‘factory’ implicated in neurodegenerative disease
Research by Waisman affiliate Jon Audhya shows new insight into the molecular basis underlying the neurodegenerative condition, hereditary spastic paraplegia (HPS). His recent study shows how a mutation in the TFG gene–one of several linked …
Unraveling the mysteries of a rare neurological disorder
Could understanding the ebb and flow of calcium in brain cells provide clues that help researchers develop a treatment for a devastating neurological disease? Rett syndrome, a rare, non-inherited neurological disorder that mostly affects girls …
Study points researchers toward new therapies for fragile X syndrome
By Adityarup “Rup” Chakravorty New insights into the molecular machinations behind fragile X syndrome, the most common inherited intellectual disability, may help researchers develop potential therapies. Fragile X is a genetic condition that affects one …
UW-Madison biomanufacturer offers essential gene-transfer capacity
Adeno-associated virus (AAV) is used to insert replacement genes, and its role in genetic therapy trials is expanding quickly, says Carl Ross, managing director of Waisman Biomanufacturing. The AAV production reflects the Waisman lab’s growing importance in the biopharma business, as it’s the only facility on campus meeting FDA “good manufacturing practices” rules for large-scale manufacturing of biological therapies.
NBC15 highlights Rett syndrome and Waisman Center research
NBC15’s Morning Show and reporter Kalie Greenberg shared a story about Laurel Cooper, a 9-year-old girl who has Rett syndrome, and her family. Rett syndrome is a rare, non-inherited neurological disorder that mostly affects girls …
A decade after stem cell feat, research ramps up
A decade after scientists announced the development of induced pluripotent stem cells, Waisman investigators, including Su-Chun Zhang and David Gamm, continue to use these cells to research and develop potential therapies for several disorders and conditions, such as ALS, Parkinson’s disease, spinal cord injury, and macular degeneration.
Waisman Biomanufacturing to be part of UW-Madison partnership in $20 million cell-based therapy center
Waisman Biomanufacturing and Waisman affiliate investigators Randolph Ashton and Krishanu Saha will be part of a new engineering research center that will develop transformative tools and technologies for the consistent, scalable and low-cost production of …